UBS Group Portfolio holdings
UBS Group AG, formed through the 1998 merger of Union Bank of Switzerland and Swiss Bank Corporation with roots dating back to 1862, is a Swiss multinational investment bank and financial services firm headquartered in Zurich. Renowned for its dominance in wealth management, UBS serves high-net-worth individuals and families globally, managing trillions in assets, while also offering investment banking, asset management, and retail banking services in Switzerland. The firm has weathered significant challenges, including a major bailout during the 2008 financial crisis, but has since refocused on stability and sustainable growth, emphasizing digital transformation and ESG (environmental, social, governance) investing. With a strong European base and a global reach, UBS remains a cornerstone of the international financial landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.12B |
| 2 |
Apple
AAPL
|
+$1.08B |
| 3 |
Microsoft
MSFT
|
+$1.05B |
| 4 |
Nike
NKE
|
+$1.03B |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$821M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$389M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$383M |
| 3 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$348M |
| 4 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$263M |
| 5 |
NRG Energy
NRG
|
+$237M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.8% |
| 2 | Financials | 8.25% |
| 3 | Healthcare | 6.4% |
| 4 | Consumer Discretionary | 5.85% |
| 5 | Communication Services | 4.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2401
Crinetics Pharmaceuticals
CRNX
$8.92B
| $8.19M | ﹤0.01% |
182,942
-64,861
| -26% | -$3M |
|
2402
Nuveen Floating Rate Income Fund
JFR
$1.25B
| $8.18M | ﹤0.01% |
945,601
+32,938
| +4% | +$287K |
|
2403
ProShares Investment Grade-Interest Rate Hedged
IGHG
$329M
| $8.18M | ﹤0.01% |
107,184
+21,462
| +25% | +$1.64M |
|
2404
PUT
Nu Holdings
NU
$66.9B
| $8.17M | ﹤0.01% |
634,200
+534,200
| +534% | +$6.22M |
|
2405
Pinnacle Financial Partners Inc
PNFP
$15.8B
| $8.17M | ﹤0.01% |
102,075
+18,330
| +22% | +$1.46M |
|
2406
Axalta
AXTA
$8.17B
| $8.14M | ﹤0.01% |
238,212
+8,756
| +4% | +$299K |
|
2407
EPR Properties
EPR
$4.77B
| $8.13M | ﹤0.01% |
193,553
-5,160
| -3% | -$212K |
|
2408
CALL
Aflac
AFL
$62.6B
| $8.11M | ﹤0.01% |
90,800
-9,300
| -9% | -$800K |
|
2409
Patterson-UTI
PTEN
$3.76B
| $8.09M | ﹤0.01% |
781,346
+292,801
| +60% | +$3.21M |
|
2410
iShares iBonds Dec 2028 Term Treasury ETF
IBTI
$1.92B
| $8.08M | ﹤0.01% |
370,342
+44,464
| +14% | +$965K |
|
2411
CALL
JD.com
JD
$44.5B
| $8.07M | ﹤0.01% |
312,484
+100,000
| +47% | +$2.93M |
|
2412
Qiagen
QGEN
$8.72B
| $8.07M | ﹤0.01% |
190,941
+44,015
| +30% | +$1.93M |
|
2413
TPG
TPG
$7.86B
| $8.07M | ﹤0.01% |
194,673
-35,286
| -15% | -$1.51M |
|
|
TPC
2414
Tutor Perini Cor
TPC
$5.21B
| $8.06M | ﹤0.01% |
369,852
+94,626
| +34% | +$1.74M |
|
2415
Ultragenyx Pharmaceutical
RARE
$2.55B
| $8.05M | ﹤0.01% |
195,891
+26,728
| +16% | +$1.14M |
|
2416
IDEAYA Biosciences
IDYA
$3.56B
| $8.03M | ﹤0.01% |
228,805
-14,244
| -6% | -$564K |
|
2417
CALL
O'Reilly Automotive
ORLY
$76.3B
| $8.03M | ﹤0.01% |
114,000
-112,500
| -50% | -$7.78M |
|
|
2418
CALL
Nu Holdings
NU
$66.9B
| $8.02M | ﹤0.01% |
622,500
-90,000
| -13% | -$1.05M |
|
2419
Element Solutions
ESI
$9.23B
| $8M | ﹤0.01% |
294,919
+14,668
| +5% | +$361K |
|
2420
RLI Corp
RLI
$5.89B
| $7.99M | ﹤0.01% |
113,618
+24,772
| +28% | +$1.77M |
|
2421
Prestige Consumer Healthcare
PBH
$2.6B
| $7.99M | ﹤0.01% |
116,002
-18,341
| -14% | -$1.24M |
|
2422
CALL
Manulife Financial
MFC
$73.5B
| $7.99M | ﹤0.01% |
300,000
| – | – |
|
|
2423
PUT
Manulife Financial
MFC
$73.5B
| $7.99M | ﹤0.01% |
300,000
| – | – |
|
2424
STAG Industrial
STAG
$7.19B
| $7.98M | ﹤0.01% |
221,251
-52,317
| -19% | -$1.86M |
|
2425
PagerDuty
PD
$902M
| $7.96M | ﹤0.01% |
347,095
-61,136
| -15% | -$1.27M |
|
Similar funds
UBS Group's Q2 2024 Portfolio in Review
As of Q2 2024, UBS Group held 10,501 positions worth $405B, up 0.81% from $402B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
UBS Group's Q2 2024 filing shows 1,231 new, 3,688 increased, 4,131 reduced and 1,043 closed positions. Its largest new stake was SLB Ltd: 10,925,731 shares worth $515M. The largest sale was BioMarin Pharmaceuticals, an estimated $389M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 15% a quarter earlier, followed by Financials and Healthcare.
- UBS Group's largest Q2 2024 buy was SLB Ltd: 10,925,731 shares worth $515M.
- UBS Group added most to NVIDIA in Q2 2024, an estimated $1.12B increase.
- UBS Group's biggest Q2 2024 reduction was BioMarin Pharmaceuticals, cutting an estimated $389M.
- UBS Group fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $263M.
- UBS Group's ten largest holdings make up 18% of its $405B portfolio in Q2 2024.
- UBS Group opened 1,231 new positions and closed 1,043 in Q2 2024.
- UBS Group's portfolio value rose 0.81% quarter-over-quarter to $405B.
Based on UBS Group's 13F filing for Q2 2024, filed 14 Aug 2024.